Brentuximab vedotin
RxNorm 1147320
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 1147320 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: brentuximab vedotin.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
Ingredient (IN):
Brentuximab vedotin
(Atom ID: 3804268)
Designated preferred name (PT):
Brentuximab vedotin
(Atom ID: 7733938)
Full form of descriptor (FN):
Brentuximab vedotin (substance)
(Atom ID: 7733941)
Designated preferred name (PT):
Brentuximab vedotin-containing product
(Atom ID: 10798298)
Full form of descriptor (FN):
Product containing brentuximab vedotin (medicinal product)
(Atom ID: 10304869)
Patient Education
Brentuximab Vedotin Injection
Brentuximab vedotin injection is used in combination with other chemotherapy medications to treat Hodgkin's lymphoma (Hodgkin's disease) in those who have not previously received treatment, to treat Hodgkin's lymphoma in those who are at risk for their disease to become worse or come back after a stem cell transplant (procedure that replaces diseased bone marrow with healthy bone marrow), to treat Hodgkin's lymphoma in those who did not respond to a stem cell transplant (procedure that replaces diseased bone marrow with healthy bone marrow) or at least two treatment periods of chemotherapy, in combination with other chemotherapy medications to treat anaplastic large cell lymphoma (sALCL; a type of non-Hodgkin lymphoma) and other certain types of peripheral T-cell lymphomas (PTCL; a type of non-Hodgkin lymphoma) in those who have not previously received treatment, to treat systemic sALCL in those who did not respond to another treatment period of chemotherapy, , to treat a certain type of primary cutaneous anaplastic large cell lymphoma (pcALCL; a type of non-Hodgkin's lymphoma) in people who have previously received another treatment. Brentuximab vedotin injection is in a class of medications called antibody-drug conjugates. It works by killing cancer cells.
[Learn More]
Cancer Chemotherapy
Normally, your cells grow and die in a controlled way. Cancer cells keep growing without control. Chemotherapy is drug therapy for cancer. It works by killing the cancer cells, stopping them from spreading, or slowing their growth. However, it can also harm healthy cells, which causes side effects.
You may have a lot of side effects, some, or none at all. It depends on the type and amount of chemotherapy you get and how your body reacts. Some common side effects are fatigue, nausea, vomiting, pain, and hair loss. There are ways to prevent or control some side effects. Talk with your health care provider about how to manage them. Healthy cells usually recover after chemotherapy is over, so most side effects gradually go away.
Your treatment plan will depend on the cancer type, the chemotherapy drugs used, the treatment goal, and how your body responds. Chemotherapy may be given alone or with other treatments. You may get treatment every day, every week, or every month. You may have breaks between treatments so that your body has a chance to build new healthy cells. You might take the drugs by mouth, in a shot, as a cream, or intravenously (by IV).
NIH: National Cancer Institute
[Learn More]
* Please review the disclaimer below.
